167 related articles for article (PubMed ID: 28026908)
1. An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus.
McEwan P; Bennett H; Qin L; Bergenheim K; Gordon J; Evans M
Diabetes Obes Metab; 2017 May; 19(5):628-634. PubMed ID: 28026908
[TBL] [Abstract][Full Text] [Related]
2. HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.
Sidorenkov G; van Boven JFM; Hoekstra T; Nijpels G; Hoogenberg K; Denig P
Diabetes Obes Metab; 2018 Aug; 20(8):1957-1964. PubMed ID: 29687577
[TBL] [Abstract][Full Text] [Related]
3. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
4. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.
Polidori D; Capuano G; Qiu R
Diabetes Obes Metab; 2016 Apr; 18(4):348-54. PubMed ID: 26661906
[TBL] [Abstract][Full Text] [Related]
5. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
[TBL] [Abstract][Full Text] [Related]
6. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
7. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
Marcinak J; Cao C; Lee D; Ye Z
Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.
Khunti K; Gomes MB; Pocock S; Shestakova MV; Pintat S; Fenici P; Hammar N; Medina J
Diabetes Obes Metab; 2018 Feb; 20(2):427-437. PubMed ID: 28834075
[TBL] [Abstract][Full Text] [Related]
9. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.
Shimoda S; Okubo M; Koga K; Sekigami T; Kawashima J; Kukidome D; Igata M; Ishii N; Shimakawa A; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
Endocr J; 2015; 62(2):209-16. PubMed ID: 25392020
[TBL] [Abstract][Full Text] [Related]
10. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
[TBL] [Abstract][Full Text] [Related]
11. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Raccah D; Gourdy P; Sagnard L; Ceriello A
Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
Park J; Park SW; Yoon KH; Kim SR; Ahn KJ; Lee JH; Mok JO; Chung CH; Han KA; Koh GP; Kang JG; Lee CB; Kim SH; Kwon NY; Kim DM
Diabetes Obes Metab; 2017 Dec; 19(12):1681-1687. PubMed ID: 28448688
[TBL] [Abstract][Full Text] [Related]
13. Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study.
Folse HJ; Mukherjee J; Sheehan JJ; Ward AJ; Pelkey RL; Dinh TA; Qin L; Kim J
Diabetes Obes Metab; 2017 Jul; 19(7):1006-1013. PubMed ID: 28211604
[TBL] [Abstract][Full Text] [Related]
14. Analysis of English general practice level data linking medication levels, service activity and demography to levels of glycaemic control being achieved in type 2 diabetes to improve clinical practice and patient outcomes.
Heald A; Davies M; Stedman M; Livingston M; Lunt M; Fryer A; Gadsby R
BMJ Open; 2019 Sep; 9(9):e028278. PubMed ID: 31494602
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of factors associated with glycaemic control in adults with Type 1 diabetes mellitus on insulin pump therapy.
Wen W; Frampton R; Wright K; Fattore S; Shadbolt B; Perampalam S
Diabet Med; 2016 Feb; 33(2):231-4. PubMed ID: 26484625
[TBL] [Abstract][Full Text] [Related]
17. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
Zhang B; Zhao J; Yang W;
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
[TBL] [Abstract][Full Text] [Related]
18. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial.
Hermanns N; Ehrmann D; Schall S; Maier B; Haak T; Kulzer B
Diabet Med; 2017 Aug; 34(8):1084-1091. PubMed ID: 28257159
[TBL] [Abstract][Full Text] [Related]
19. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
